share_log

Panbela Therapeutics | UPLOAD: Others

Panbela Therapeutics | UPLOAD: Others

Panbela Therapeutics | UPLOAD:其他
美股SEC公告 ·  04/02 12:45

Moomoo AI 已提取核心信息

Panbela Therapeutics, Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on March 29, 2024, will not undergo review. The SEC's communication, dated April 2, 2024, was addressed to Jennifer Simpson, CEO of Panbela Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Jessica Dickerson from the Division of Corporation Finance Office of Life Sciences.
Panbela Therapeutics, Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on March 29, 2024, will not undergo review. The SEC's communication, dated April 2, 2024, was addressed to Jennifer Simpson, CEO of Panbela Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Jessica Dickerson from the Division of Corporation Finance Office of Life Sciences.
美国证券交易委员会(SEC)已告知生物制药公司Panbela Therapeutics, Inc.,其于2024年3月29日提交的S-1表格的注册声明将不接受审查。美国证券交易委员会于2024年4月2日发给了Panbela Therapeutics首席执行官詹妮弗·辛普森的来文。美国证券交易委员会的信中引用了第460和461条,这两条规则与加快注册程序的请求有关。此外,美国证券交易委员会提醒该公司及其管理层,无论美国证券交易委员会的审查程度如何,他们都对披露的准确性和充分性负责。为了进一步调查,美国证券交易委员会提供了生命科学公司财务部杰西卡·迪克森的联系信息。
美国证券交易委员会(SEC)已告知生物制药公司Panbela Therapeutics, Inc.,其于2024年3月29日提交的S-1表格的注册声明将不接受审查。美国证券交易委员会于2024年4月2日发给了Panbela Therapeutics首席执行官詹妮弗·辛普森的来文。美国证券交易委员会的信中引用了第460和461条,这两条规则与加快注册程序的请求有关。此外,美国证券交易委员会提醒该公司及其管理层,无论美国证券交易委员会的审查程度如何,他们都对披露的准确性和充分性负责。为了进一步调查,美国证券交易委员会提供了生命科学公司财务部杰西卡·迪克森的联系信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息